Modified tunicamycins, streptovirudins and quinovosamycins: potent enhancers of the penicillin antibiotics

<none>

Programme Social programme Plenary speakers Keynote speakers 1st EuroCarb Young Researcher (ECYR) Workshop CarboMet Workshop Mini symposium: Glycobiology at the LUMC and beyond Favourites/Agenda

Social programme

Plenary speakers

Keynote speakers

1st EuroCarb Young Researcher (ECYR) Workshop

CarboMet Workshop

Mini symposium: Glycobiology at the LUMC and beyond

Favourites/Agenda

Photos

Venue & Travel Venue Accommodation City of Leiden Travel directions

Venue

Accommodation

City of Leiden

Travel directions

Committees

Home

Modified tunicamycins, streptovirudins and quinovosamycins: potent enhancers of the penicillin antibiotics

Neil Price 1 , Michael Jackson 1 , Todd Naumann 1 , John Bannantine 1 , Jenny Hering 2 , Gisela Branden 3 , Margareta Ek 2 , Vinayak Singh 5 , Valerie Mizrahi 5 , Katarina Mikusova 4

1 U.S. Department of Agriculture, Peoria, United States, 2 AstraZeneca Ltd., Gothenburg, Sweden, 3 University of Gothenburg, Gothenburg, Sweden, 4 Comenius University, Bratislava, Slovakia, 5 University of Cape Town, Cape Town, South Africa

Tunicamycin is lethal to bacteria and eukaryotes either by blocking cell wall biosynthesis or protein N-glycosylation, respectively. The tunicamycin uracil group mimics the UDP-HexNAc donor substrate, binding to a uridyl binding pocket within PNPT translocase enzymes. This is stabilized by a noncovalent π–πstacking interaction with a conserved Phe within the PNPT active site. We have structurally modified tunicamycins (TunR1 and TunR2) to be less toxic to animal cells, but which retain the antibacterial activity. TunR1 and TunR2 are also potent enhancers of the β-lactam family of antibiotics, resulting in increased activity of penicillins, cephems, and carbapenems. TunR2 in which the uridyl group is converted to a 5,6-dihydrouridyl has low eukaryotic toxicity, and enhanced aminothiazolidyl cephalosporins by >128-fold against B. subtilis and several pathogenic mycobacterial strains.

Contact eurocarb@eurocarb2019.com for general questions about EUROCARB2019, or codee@eurocarb2019.com for scientific questions.

Leiden University / Leiden Institute of Chemistry lic.leidenuniv.nl

European Carbohydrate Organisation

Congress by Design www.congressbydesign.com